Arcturus announces medRxiv preprint of Phase 3 data for ARCT-154 booster vs. Comirnaty

Arcturus Therapeutics Holdings Inc.

Preprint on medRxiv reports interim Phase 3 results from Japan comparing ARCT-154 booster to Comirnaty.
Study conducted by Meiji Seika Pharma, Arcturus' collaborator, evaluating safety and immunogenicity.
Meiji has a distribution agreement with CSL Seqirus for ARCT-154 in Japan, previously announced on April 11, 2023.
The article is a preprint and has not yet been peer-reviewed; no specific results are provided in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.